Compare Jabil Inc (JBL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Mesoblast Limited — how do they compare? Jabil Inc trades at $303 (market cap $31.38B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Jabil Inc is far larger — about 17.3× Mesoblast Limited's market cap, and Jabil Inc pays a 0.11% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Mesoblast Limited for 14 Days on average.
| JBL | MESO | |
|---|---|---|
Market Cap | $31.38B | $1.81B |
Volume | 1,418,629 | 240,620 |
Sector | Technology | Health |
52-Week High | $385.50 | $20.96 |
52-Week Low | $192.49 | $13.19 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $33.66B | $1.89B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.47, down 3.14% today amid a bearish technical signal, though recent Q4 2026 earnings beat expectations with EPS of $4.40 versus $4.07 expected. The company shows strong fundamentals with revenue growth to $29.80B in 2025 and projected 24% growth in fiscal 2027 driven by AI infrastructure demand. Analyst consensus remains bullish with a $434.75 price target, representing 45% upside potential from current levels.
The stock presents a compelling growth opportunity with robust AI-driven expansion and strong institutional support, though technical weakness and market volatility pose near-term risks. With zero sell ratings and 61% buy recommendations, Wall Street sees significant upside despite recent price pressure from broader market sentiment.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
